Apoptosis: a
cytotoxicity, immunologic
immunotherapy, adoptive
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
accepted:
04
02
2023
medline:
17
4
2023
entrez:
13
4
2023
pubmed:
14
4
2023
Statut:
ppublish
Résumé
Immunotherapy has revolutionized the treatment of cancer. In particular, immune checkpoint blockade, bispecific antibodies, and adoptive T-cell transfer have yielded unprecedented clinical results in hematological malignancies and solid cancers. While T cell-based immunotherapies have multiple mechanisms of action, their ultimate goal is achieving apoptosis of cancer cells. Unsurprisingly, apoptosis evasion is a key feature of cancer biology. Therefore, enhancing cancer cells' sensitivity to apoptosis represents a key strategy to improve clinical outcomes in cancer immunotherapy. Indeed, cancer cells are characterized by several intrinsic mechanisms to resist apoptosis, in addition to features to promote apoptosis in T cells and evade therapy. However, apoptosis is double-faced: when it occurs in T cells, it represents a critical mechanism of failure for immunotherapies. This review will summarize the recent efforts to enhance T cell-based immunotherapies by increasing apoptosis susceptibility in cancer cells and discuss the role of apoptosis in modulating the survival of cytotoxic T lymphocytes in the tumor microenvironment and potential strategies to overcome this issue.
Identifiants
pubmed: 37055217
pii: jitc-2022-005967
doi: 10.1136/jitc-2022-005967
pmc: PMC10106075
pii:
doi:
Types de publication
Journal Article
Review
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCI NIH HHS
ID : T32 CA009615
Pays : United States
Organisme : NCI NIH HHS
ID : R00 CA212302
Pays : United States
Organisme : NCI NIH HHS
ID : K99 CA212302
Pays : United States
Informations de copyright
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: M. Ruella reports grants from the Mark Foundation, Upenn TAPITMAT, the Lymphoma Research Foundation, the NCI (1K99CA212302 and R00CA212302), the Parker Institute for Cancer Immunotherapy, and the Berman and Maguire Funds for Lymphoma Research at the University of Pennsylvania during the conduct of the study; grants from Novartis outside the submitted work; a patent for BCL-2 and CART pending; is listed as an inventor of CART technologies, University of Pennsylvania, partly licensed to Novartis, Tmunity, and viTToria Biotherapeutics; research funding from AbClon, Beckman Coulter, Lumicks, and ONI; consultancy for/honoraria from NanoString Technologies Inc. and GLG; advisory boards for AbClon, Bayer, Sana, Bristol Myers Squibb, GSK, and viTToria Biotherapeutics; and is a scientific founder of viTToria Biotherapeutics. No disclosures were reported by the other authors.
Références
Cancer Res. 2011 Jul 1;71(13):4423-31
pubmed: 21546572
J Immunother Cancer. 2018 Jul 13;6(1):71
pubmed: 30005714
N Engl J Med. 2021 Feb 18;384(7):673-674
pubmed: 33596362
N Engl J Med. 2018 Feb 1;378(5):439-448
pubmed: 29385370
Lancet. 2021 Jul 24;398(10297):314-324
pubmed: 34175021
J Immunol. 2006 Jan 15;176(2):778-89
pubmed: 16393961
Cell. 2015 Sep 10;162(6):1229-41
pubmed: 26321679
PLoS One. 2012;7(2):e31762
pubmed: 22389673
Front Immunol. 2021 May 05;12:626616
pubmed: 34025638
Proc Natl Acad Sci U S A. 2006 Dec 5;103(49):18703-8
pubmed: 17116875
Oncologist. 2006 Apr;11(4):342-57
pubmed: 16614230
Blood. 2020 Feb 27;135(9):597-609
pubmed: 31830245
Cancer Res. 2009 Apr 1;69(7):3095-104
pubmed: 19276353
J Immunol. 2008 Mar 1;180(5):3091-102
pubmed: 18292532
Cell Death Dis. 2015 Jun 18;6:e1792
pubmed: 26086965
Oncotarget. 2017 Jul 25;8(30):49824-49838
pubmed: 28548942
Cancer Immunol Res. 2019 Feb;7(2):183-192
pubmed: 30651288
Cell Death Differ. 2002 Oct;9(10):1069-77
pubmed: 12232795
Nat Rev Immunol. 2009 Apr;9(4):271-85
pubmed: 19319144
Nat Med. 2013 Feb;19(2):202-8
pubmed: 23291630
Cancer Discov. 2022 Oct 5;12(10):2372-2391
pubmed: 35904479
J Virol. 2015 Feb;89(4):2405-14
pubmed: 25505074
Int J Cancer. 2013 Oct 1;133(7):1643-52
pubmed: 23504627
J Clin Oncol. 2006 Dec 1;24(34):5373-80
pubmed: 17135638
Cold Spring Harb Perspect Med. 2014 Jul 01;4(7):a014407
pubmed: 24985130
Clin Cancer Res. 2005 Feb 1;11(3):1010-20
pubmed: 15709166
J Biol Chem. 1996 Nov 15;271(46):29073-9
pubmed: 8910561
Annu Rev Biochem. 2000;69:217-45
pubmed: 10966458
J Neuropathol Exp Neurol. 2014 Nov;73(11):1034-46
pubmed: 25289891
Nat Rev Cancer. 2004 Nov;4(11):891-9
pubmed: 15516961
Glycoconj J. 2004;20(4):247-55
pubmed: 15115909
Pathology. 2004 Dec;36(6):561-5
pubmed: 15841691
N Engl J Med. 2018 Nov 22;379(21):2040-2051
pubmed: 30280635
Nat Commun. 2019 Jun 3;10(1):2385
pubmed: 31160589
Eur J Immunol. 1998 Feb;28(2):560-9
pubmed: 9521066
Oncotarget. 2017 Mar 7;8(10):17002-17011
pubmed: 28199983
Cell Mol Immunol. 2010 Jan;7(1):77-82
pubmed: 20029460
Immunol Lett. 2000 Apr 3;72(1):39-48
pubmed: 10789680
Tumour Biol. 2015 Jul;36(7):5617-26
pubmed: 25725585
Nat Immunol. 2013 May;14(5):500-8
pubmed: 23525088
Clin Cancer Res. 2015 Sep 15;21(18):4035-9
pubmed: 26374073
Mol Pharmacol. 2008 Mar;73(3):738-47
pubmed: 18079278
Trends Biochem Sci. 2016 Mar;41(3):211-218
pubmed: 26778478
Exp Cell Res. 1997 Aug 1;234(2):341-6
pubmed: 9260903
J Immunol. 2004 Sep 15;173(6):3825-37
pubmed: 15356130
Clin Cancer Res. 2003 Aug 15;9(9):3397-405
pubmed: 12960128
Oncogene. 2007 Feb 26;26(9):1324-37
pubmed: 17322918
Mol Ther Oncolytics. 2022 Nov 15;27:288-304
pubmed: 36458202
J Biochem. 2007 Feb;141(2):157-72
pubmed: 17167046
N Engl J Med. 2021 Feb 25;384(8):705-716
pubmed: 33626253
Cancer Sci. 2017 Sep;108(9):1739-1745
pubmed: 28699227
J Clin Invest. 2019 Feb 25;129(4):1551-1565
pubmed: 30694219
J Exp Med. 2002 May 20;195(10):1303-16
pubmed: 12021310
Cell Death Differ. 2008 Jan;15(1):70-9
pubmed: 18007660
Transl Oncol. 2018 Oct;11(5):1171-1187
pubmed: 30059832
Exp Cell Res. 2017 Jan 1;350(1):140-146
pubmed: 27884681
Immunol Rev. 2003 Jun;193:70-81
pubmed: 12752672
Immunity. 2006 Jun;24(6):703-716
pubmed: 16782027
Cancers (Basel). 2011 Mar 03;3(1):994-1013
pubmed: 24212651
Cancers (Basel). 2021 Jan 08;13(2):
pubmed: 33429845
Blood. 2015 Jan 22;125(4):658-67
pubmed: 25452615
J Hematol Oncol. 2018 May 11;11(1):65
pubmed: 29747654
Br J Cancer. 2004 Jul 5;91(1):164-70
pubmed: 15188008
Clin Invest Med. 2010 Feb 01;33(1):E44-53
pubmed: 20144269
Glycoconj J. 2004;19(7-9):433-40
pubmed: 14758066
Front Immunol. 2020 May 12;11:888
pubmed: 32477359
Science. 1996 Nov 22;274(5291):1363-6
pubmed: 8910274
Nat Rev Immunol. 2015 Jun;15(6):388-400
pubmed: 25998963
Genome Biol. 2001;2(12):REVIEWS3014
pubmed: 11790262
J Exp Med. 1996 Sep 1;184(3):1075-82
pubmed: 9064324
BMC Med. 2016 May 05;14:73
pubmed: 27151159
Biochem Biophys Res Commun. 2011 Dec 9;416(1-2):222-5
pubmed: 22120628
Nat Rev Drug Discov. 2022 Jun;21(6):411-412
pubmed: 35246638
Science. 2018 Mar 23;359(6382):1361-1365
pubmed: 29567707
Int J Oncol. 2005 May;26(5):1273-81
pubmed: 15809718
Front Immunol. 2016 Sep 27;7:382
pubmed: 27729910
J Clin Invest. 2019 Dec 2;129(12):5553-5567
pubmed: 31710313
Cancer Res. 2005 Jun 15;65(12):5428-38
pubmed: 15958592
J Immunol. 2000 Apr 15;164(8):3950-4
pubmed: 10754284
Trends Immunol. 2015 Apr;36(4):265-76
pubmed: 25797516
J Clin Pathol. 2006 Jul;59(7):716-20
pubmed: 16489180
Nat Med. 2004 Sep;10(9):942-9
pubmed: 15322536
Front Mol Biosci. 2019 Oct 15;6:106
pubmed: 31681794
Br J Cancer. 2005 Jan 31;92(2):305-11
pubmed: 15655551
Br J Cancer. 2006 Nov 6;95(9):1244-9
pubmed: 17031406
Immunology. 2010 Apr;129(4):474-81
pubmed: 20201977
Cancer Res. 2003 Apr 1;63(7):1676-83
pubmed: 12670922
Nat Commun. 2017 Feb 15;8:
pubmed: 28198370
Immunol Today. 1995 Apr;16(4):194-201
pubmed: 7734048
Cancer Res. 2004 Nov 1;64(21):7985-94
pubmed: 15520206
J Biol Chem. 2009 May 8;284(19):12670-9
pubmed: 19276072
Expert Opin Biol Ther. 2015 Jun;15(6):761-6
pubmed: 25640460
N Engl J Med. 2019 Jan 3;380(1):45-56
pubmed: 30501490
Cancer Res. 2012 Jun 1;72(11):2746-56
pubmed: 22593198
Cancer Res. 1997 Mar 15;57(6):1007-12
pubmed: 9067260
Oncoimmunology. 2014 Dec 21;3(11):e970027
pubmed: 25941599
Cells. 2020 Feb 11;9(2):
pubmed: 32053868
Nat Med. 2018 May;24(5):563-571
pubmed: 29713085
Nat Rev Immunol. 2016 Sep;16(9):553-65
pubmed: 27396447
Cancer Gene Ther. 2013 Jul;20(7):386-93
pubmed: 23788110
EMBO J. 2005 Feb 9;24(3):645-55
pubmed: 15650747
Mol Cancer Res. 2010 May;8(5):729-38
pubmed: 20442297
Eur J Immunol. 2013 Apr;43(4):889-96
pubmed: 23310952
Sci Rep. 2017 Sep 5;7(1):10541
pubmed: 28874817
Eur J Biochem. 1998 Jun 15;254(3):439-59
pubmed: 9688254
Clin Cancer Res. 2015 Nov 15;21(22):5047-56
pubmed: 26567364
BMC Cancer. 2017 Jun 2;17(1):399
pubmed: 28578655
Oncogene. 2002 Apr 4;21(15):2283-94
pubmed: 11948412
Nat Commun. 2019 Sep 2;10(1):3959
pubmed: 31477729
Blood. 2014 Jan 30;123(5):659-68
pubmed: 24335231
Cell Rep. 2017 Oct 3;21(1):17-26
pubmed: 28978471
PLoS One. 2013 Jun 06;8(6):e65145
pubmed: 23762301
Cancer Discov. 2021 Jan;11(1):68-79
pubmed: 32887697
Expert Rev Mol Med. 2008 Jun 13;10:e17
pubmed: 18549522
Am J Pathol. 2006 May;168(5):1666-75
pubmed: 16651632
Oncoimmunology. 2020 Jan 9;9(1):1710398
pubmed: 32002309
Nature. 1995 Dec 14;378(6558):736-9
pubmed: 7501023
Cells. 2013 Mar 14;2(1):163-87
pubmed: 24709650
Cancer Discov. 2020 Apr;10(4):552-567
pubmed: 32001516
Cancer Res. 2005 Mar 1;65(5):2001-8
pubmed: 15753400
Nat Commun. 2017 Nov 10;8(1):1404
pubmed: 29123081
Cancer Immunol Res. 2015 Apr;3(4):368-79
pubmed: 25576337
Immunity. 2016 Jun 21;44(6):1255-69
pubmed: 27332730
Biochem Pharmacol. 2012 Aug 1;84(3):402-10
pubmed: 22483777
Cancer Res. 2003 Dec 1;63(23):8302-11
pubmed: 14678989
Front Immunol. 2020 Dec 09;11:608167
pubmed: 33362794
Nat Med. 1996 Dec;2(12):1361-6
pubmed: 8946836
Cancer Discov. 2021 Mar;11(3):599-613
pubmed: 33334730
Nat Rev Drug Discov. 2012 Feb 01;11(2):109-24
pubmed: 22293567
N Engl J Med. 2017 Dec 28;377(26):2531-2544
pubmed: 29226797
Blood. 1995 Aug 15;86(4):1255-60
pubmed: 7632929
Int J Mol Sci. 2021 Mar 11;22(6):
pubmed: 33799592
Nat Rev Cancer. 2005 Jan;5(1):29-41
pubmed: 15630413
Front Biosci (Schol Ed). 2012 Jan 01;4(2):502-19
pubmed: 22202073
Cancer Res. 2008 Sep 1;68(17):7228-36
pubmed: 18757439
Int J Cancer. 2006 Oct 1;119(7):1630-7
pubmed: 16646079
Immunity. 2011 Dec 23;35(6):871-82
pubmed: 22195744
Nat Rev Drug Discov. 2019 Aug;18(8):585-608
pubmed: 31175342
Mol Cancer. 2019 Jan 15;18(1):10
pubmed: 30646912
Biochim Biophys Acta. 2006 Apr;1760(4):616-35
pubmed: 16478649
Clin Cancer Res. 2003 Nov 1;9(14):5113-9
pubmed: 14613988
N Engl J Med. 2020 Apr 2;382(14):1331-1342
pubmed: 32242358
Int J Cancer. 2009 Feb 1;124(3):511-5
pubmed: 19003982